| | Business Summary | | Gliatech
Inc.
is
engaged
in
the
discovery
and
development
of
biosurgery
and
pharmaceutical
products.
The
biosurgery
products
include
ADCON
gel
and
ADCON
solution,
which
are
proprietary,
resorbable,
carbohydrate
polymer
medical
devices
designed
to
inhibit
scarring
and
adhesions
following
surgery.
Gliatech's
pharmaceutical
product
candidates
include
small
molecule
drugs
to
modulate
the
cognitive
state
of
the
nervous
system
and
proprietary
monoclonal
antibodies
designed
to
treat
inflammatory
disorders. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Gliatech
Inc.
is
engaged
in
the
research,
development
and
commercialization
of
proprietary,
resorbable,
carbohydrate
polymer
medical
devices
designed
to
inhibit
surgical
scarring
and
adhesions.
For
the
six
months
ended
6/30/01,
revenues
fell
92%
to
$1.1
million.
Net
loss
totaled
$11.4
million,
up
from
$113
thousand.
Results
reflect
reduced
product
sales
due
to
the
Company's
voluntary
recall
of
ADCON-L
and
ADCON-T/N
in
January
2001. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Robert Pinkas, 47
Acting
Chairman, CEO | -- | Steven Basta, 35
Pres,
Director | -- | Thomas Barnish, 53
CFO,
VP-Fin. | -- | Clark Tedford, Ph.D., 42
Exec.
VP of R&D | $193K | Robert Bard
VP, Regulatory Affairs | -- | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/g/glia.gif)